204 related articles for article (PubMed ID: 19558491)
1. Design and humanization of a murine scFv that blocks human platelet glycoprotein VI in vitro.
Muzard J; Bouabdelli M; Zahid M; Ollivier V; Lacapère JJ; Jandrot-Perrus M; Billiald P
FEBS J; 2009 Aug; 276(15):4207-22. PubMed ID: 19558491
[TBL] [Abstract][Full Text] [Related]
2. Anti-glycoprotein VI monoclonal antibodies directly aggregate platelets independently of FcgammaRIIa and induce GPVI ectodomain shedding.
Al-Tamimi M; Mu FT; Arthur JF; Shen Y; Moroi M; Berndt MC; Andrews RK; Gardiner EE
Platelets; 2009 Mar; 20(2):75-82. PubMed ID: 19235048
[TBL] [Abstract][Full Text] [Related]
3. Highly potent anti-human GPVI monoclonal antibodies derived from GPVI knockout mouse immunization.
Matsumoto Y; Takizawa H; Gong X; Le S; Lockyer S; Okuyama K; Tanaka M; Yoshitake M; Tandon NN; Kambayashi J
Thromb Res; 2007; 119(3):319-29. PubMed ID: 16566959
[TBL] [Abstract][Full Text] [Related]
4. Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived Fab fragments.
Lecut C; Feeney LA; Kingsbury G; Hopkins J; Lanza F; Gachet C; Villeval JL; Jandrot-Perrus M
J Thromb Haemost; 2003 Dec; 1(12):2653-62. PubMed ID: 14675102
[TBL] [Abstract][Full Text] [Related]
5. Principal role of glycoprotein VI in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation.
Lecut C; Schoolmeester A; Kuijpers MJ; Broers JL; van Zandvoort MA; Vanhoorelbeke K; Deckmyn H; Jandrot-Perrus M; Heemskerk JW
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1727-33. PubMed ID: 15231520
[TBL] [Abstract][Full Text] [Related]
6. The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats.
Li H; Lockyer S; Concepcion A; Gong X; Takizawa H; Guertin M; Matsumoto Y; Kambayashi J; Tandon NN; Liu Y
Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1199-205. PubMed ID: 17322098
[TBL] [Abstract][Full Text] [Related]
7. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo.
Massberg S; Konrad I; Bültmann A; Schulz C; Münch G; Peluso M; Lorenz M; Schneider S; Besta F; Müller I; Hu B; Langer H; Kremmer E; Rudelius M; Heinzmann U; Ungerer M; Gawaz M
FASEB J; 2004 Feb; 18(2):397-9. PubMed ID: 14656994
[TBL] [Abstract][Full Text] [Related]
8. Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy.
Grüner S; Prostredna M; Aktas B; Moers A; Schulte V; Krieg T; Offermanns S; Eckes B; Nieswandt B
Circulation; 2004 Nov; 110(18):2946-51. PubMed ID: 15505105
[TBL] [Abstract][Full Text] [Related]
9. Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo.
Schulz C; Penz S; Hoffmann C; Langer H; Gillitzer A; Schneider S; Brandl R; Seidl S; Massberg S; Pichler B; Kremmer E; Stellos K; Schönberger T; Siess W; Gawaz M
Basic Res Cardiol; 2008 Jul; 103(4):356-67. PubMed ID: 18431526
[TBL] [Abstract][Full Text] [Related]
10. Design and reshaping of an scFv directed against human platelet glycoprotein VI with diagnostic potential.
Zahid M; Loyau S; Bouabdelli M; Aubrey N; Jandrot-Perrus M; Billiald P
Anal Biochem; 2011 Oct; 417(2):274-82. PubMed ID: 21771576
[TBL] [Abstract][Full Text] [Related]
11. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding.
Kleinschnitz C; Pozgajova M; Pham M; Bendszus M; Nieswandt B; Stoll G
Circulation; 2007 May; 115(17):2323-30. PubMed ID: 17438148
[TBL] [Abstract][Full Text] [Related]
12. A humanized glycoprotein VI (GPVI) mouse model to assess the antithrombotic efficacies of anti-GPVI agents.
Mangin PH; Tang C; Bourdon C; Loyau S; Freund M; Hechler B; Gachet C; Jandrot-Perrus M
J Pharmacol Exp Ther; 2012 Apr; 341(1):156-63. PubMed ID: 22238212
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo evaluation of anti-GPVI antibody in cynomolgus monkeys: dissociation between anti-platelet aggregatory effect and bleeding time.
Matsumoto Y; Takizawa H; Nakama K; Gong X; Yamada Y; Tandon NN; Kambayashi J
Thromb Haemost; 2006 Aug; 96(2):167-75. PubMed ID: 16894460
[TBL] [Abstract][Full Text] [Related]
14. Collagen-type specificity of glycoprotein VI as a determinant of platelet adhesion.
Jung SM; Takemura Y; Imamura Y; Hayashi T; Adachi E; Moroi M
Platelets; 2008 Feb; 19(1):32-42. PubMed ID: 18231936
[TBL] [Abstract][Full Text] [Related]
15. EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on atherothrombosis.
Grothusen C; Umbreen S; Konrad I; Stellos K; Schulz C; Schmidt B; Kremmer E; Teebken O; Massberg S; Luchtefeld M; Schieffer B; Gawaz M
Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1184-90. PubMed ID: 17347483
[TBL] [Abstract][Full Text] [Related]
16. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.
Staelens S; Desmet J; Ngo TH; Vauterin S; Pareyn I; Barbeaux P; Van Rompaey I; Stassen JM; Deckmyn H; Vanhoorelbeke K
Mol Immunol; 2006 Mar; 43(8):1243-57. PubMed ID: 16118019
[TBL] [Abstract][Full Text] [Related]
17. Anti GPVI human antibodies neutralizing collagen-induced platelet aggregation isolated from a combinatorial phage display library.
Qian MD; Villeval JL; Xiong X; Jandrot-Perrus M; Nagashima K; Tonra J; McDonald K; Goodearl A; Gill D
Hum Antibodies; 2002; 11(3):97-105. PubMed ID: 12454370
[TBL] [Abstract][Full Text] [Related]
18. Trowaglerix Venom Polypeptides As a Novel Antithrombotic Agent by Targeting Immunoglobulin-Like Domains of Glycoprotein VI in Platelet.
Chang CH; Chung CH; Tu YS; Tsai CC; Hsu CC; Peng HC; Tseng YJ; Huang TF
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1307-1314. PubMed ID: 28596377
[TBL] [Abstract][Full Text] [Related]
19. Identification of human platelet glycoprotein VI-specific IgG autoantibody and its fragments.
Chu X; Hou M; Peng J; Zhu Y; Zhang F; Ji X; Wang L; Ma D
Blood Coagul Fibrinolysis; 2006 Jul; 17(5):403-7. PubMed ID: 16788317
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan (DuP-753) via glycoprotein VI.
Ono K; Ueda H; Yoshizawa Y; Akazawa D; Tanimura R; Shimada I; Takahashi H
J Med Chem; 2010 Mar; 53(5):2087-93. PubMed ID: 20158191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
